Home ›
Leukemia Trials ›
NCT04581512
Study to Evaluate the Safety and Tolerability of EP0042
A research study looking at a new treatment for patients with advanced cancer, to investigate different doses of the experimental study drug, EP0042, in order to determine a dose, which is safe, well-tolerated and likely to be effective in treating AML (acute myeloid leukaemia).
Trial Details
NCT ID NCT04581512
Phase PHASE1 / PHASE2
Sponsor Ellipses Pharma
Status RECRUITING
Cancer Type Leukemia
Interventions EP0042 Venetoclax Azacitidine (AZA)
Locations (sample) Perth, Western Australia, Australia|-31.95224,115.8614 Amsterdam, Netherlands|52.37403,4.88969 Rotterdam, Netherlands|51.9225,4.47917 London, UK, United Kingdom|51.50853,-0.12574 London, United Kingdom|51.50853,-0.12574
Key Eligibility Criteria
Male or female patients aged ≥ 18 years of age, at the time of informed consent, with histological or cytological confirmation of AML Ability to understand and provide written informed consent before any study-specific procedures, sampling, or analyses, including access to archiva… Ability to swallow and retain oral medication Sufficient life expectancy to allow the patient to complete at least 1 cycle (28 days) of the treatment period.
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →